Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Chicago, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, University of Münster, University Hospital Münster, Dana-Farber Cancer Institute, Goethe University Frankfurt, Cleveland Clinic, University of California, Irvine, Stanford Medicine, Stanford University, University of Southern California, University of Washington, Fred Hutch Cancer Center, Pfizer (United States), The University of Texas MD Anderson Cancer Center
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891957005